Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 36.8%

MDxHealth SA (NASDAQ:MDXH) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 24,600 shares, a drop of 36.8% from the November 30th total of 38,900 shares. Based on an average daily volume of 153,400 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the stock are sold short.

MDxHealth Price Performance

MDxHealth stock opened at $2.31 on Monday. The stock has a market cap of $3.60 million, a price-to-earnings ratio of -1.52 and a beta of 1.42. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The business has a 50-day simple moving average of $2.04 and a 200 day simple moving average of $2.40. MDxHealth has a 52 week low of $1.55 and a 52 week high of $4.64.

Institutional Trading of MDxHealth

Large investors have recently modified their holdings of the business. OneDigital Investment Advisors LLC increased its position in shares of MDxHealth by 15.3% in the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares during the last quarter. Maven Securities LTD purchased a new position in MDxHealth in the 3rd quarter worth approximately $208,000. Perkins Capital Management Inc. increased its holdings in shares of MDxHealth by 70.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after buying an additional 309,500 shares during the last quarter. Finally, MVM Partners LLC raised its position in shares of MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after buying an additional 150,000 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler decreased their price target on MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Lake Street Capital initiated coverage on shares of MDxHealth in a report on Thursday, October 31st. They set a “buy” rating and a $7.00 target price on the stock.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.